Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. The Michel Clavel lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998

Annals of Oncology

Volumn 9, Issue 10, 1998, Pages 1047-1052

  Eisenhauer, E A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Phase I; Phase II; Response; Toxicity

Indexed keywords

ACIVICIN; ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; EDATREXATE; ELSAMICIN A; GEMCITABINE; IFOSFAMIDE; ISOTRETINOIN; MENOGARIL; PACLITAXEL; TELOXANTRONE; TIAZOFURIN; TOPOTECAN; TRIMETREXATE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TARGETING; EXISTENTIALISM; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TOXICITY TESTING; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; TREATMENT OUTCOME;

EID: 0031797332     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008497110734     Document Type: Conference Paper

References (9)

1. Rustin GJS, Nelstrop AE, Bolis G et al. Use of CA125 to assess activity of topotecan versus paclitaxel in relapsed ovarian carcinoma measured by response and early progression. Proc Am Soc Clin Oncol 1997; 16: 351a (Abstr).
2. Rasmussen H, Rugg T, Brown P et al. A 371 patient meta-analysis of studies of marimastal in patients with advanced cancer. Proc Am Soc Clin Oncol 1997; 16: 429a (Abstr).
3. Thalmann GN, Sikes RA, Chang SM et al. Suramin-induced decrease in prostate specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996; 88: 794-810.
4. Timothy AR, Cook GJR. PET scanning in clinical oncology. Ann Oncol 1998; 9: 353-5.
5. Zee B, Melnychuk D, Dancey J et al. A new design of phase II cancer clinical trials incorporating response and early progression. Controll Clin Trials 1996; 17: 85S (Abstr A80).
6. Dent S, Zee B, Dancey J et al. Design of phase II clinical trials - stopping rule using response and early progression. Ann Oncol 1996; 7 (Suppl 1): 134 (Abstr).
7. Rapp E, Pater JL, Willan A et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-41.
8. Murray N, Coppin C, Coldman A et al. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer. J Clin Oncol 1994; 12: 2333-9.
9. Fleming TR. One sample multiple testing procedures for phase II trials. Biometrics 1982; 38: 143-51.